KR101645752B1 - 신규의 프로스타글란딘 ｉ2 유도체 - Google Patents

신규의 프로스타글란딘 ｉ2 유도체 Download PDF

Info

Publication number
KR101645752B1
KR101645752B1 KR1020117007958A KR20117007958A KR101645752B1 KR 101645752 B1 KR101645752 B1 KR 101645752B1 KR 1020117007958 A KR1020117007958 A KR 1020117007958A KR 20117007958 A KR20117007958 A KR 20117007958A KR 101645752 B1 KR101645752 B1 KR 101645752B1
Authority
KR
South Korea
Prior art keywords
group
ulcer
disease
derivative
prostaglandin
Prior art date
Application number
KR1020117007958A
Other languages
English (en)
Korean (ko)
Other versions
KR20110051286A (ko
Inventor
다카히코 무라타
마사히로 아마카와
신 데라다이라
야스시 마츠무라
가츠히코 고니시
Original Assignee
아사히 가라스 가부시키가이샤
가껭세이야꾸가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아사히 가라스 가부시키가이샤, 가껭세이야꾸가부시기가이샤 filed Critical 아사히 가라스 가부시키가이샤
Publication of KR20110051286A publication Critical patent/KR20110051286A/ko
Application granted granted Critical
Publication of KR101645752B1 publication Critical patent/KR101645752B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117007958A 2008-09-10 2009-09-08 신규의 프로스타글란딘 ｉ2 유도체 KR101645752B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2008-232133 2008-09-10
JP2008232133 2008-09-10
JPJP-P-2009-168193 2009-07-16
JP2009168193 2009-07-16

Publications (2)

Publication Number Publication Date
KR20110051286A KR20110051286A (ko) 2011-05-17
KR101645752B1 true KR101645752B1 (ko) 2016-08-04

Family

ID=42005178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117007958A KR101645752B1 (ko) 2008-09-10 2009-09-08 신규의 프로스타글란딘 ｉ2 유도체

Country Status (15)

Country Link
US (4) US8394844B2 (pl)
EP (1) EP2343292B1 (pl)
JP (1) JP5468007B2 (pl)
KR (1) KR101645752B1 (pl)
CN (1) CN102209719B (pl)
AU (1) AU2009292555B2 (pl)
BR (1) BRPI0918134B1 (pl)
CA (1) CA2736039C (pl)
DK (1) DK2343292T3 (pl)
ES (1) ES2522971T3 (pl)
MX (1) MX2011002573A (pl)
PL (1) PL2343292T3 (pl)
PT (1) PT2343292E (pl)
RU (1) RU2509768C2 (pl)
WO (1) WO2010029925A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918134B1 (pt) 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
DK2545917T3 (en) * 2010-03-08 2016-11-14 Kaken Pharma Co Ltd NEW EP4 AGONIST.
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
ES2767583T3 (es) * 2012-10-26 2020-06-18 Agc Inc Método para fabricar un compuesto de difluorolactona
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
EP3282937A4 (en) * 2015-04-14 2018-11-21 Nueon Inc. Method and apparatus for determining markers of health by analysis of blood
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
JPWO2021070658A1 (pl) * 2019-10-11 2021-04-15
HU231350B1 (hu) 2019-12-18 2023-01-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt Eljárás királis prosztaglandin-enol intermedier előállítására, és az eljárásban hasznos köztitermék vegyületek

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747531A (en) 1994-02-17 1998-05-05 Asahi Glass Company Ltd. Difluoroprostacyclins
JP2004256547A (ja) 1994-03-17 2004-09-16 Asahi Glass Co Ltd ジハロゲン化プロスタサイクリン類の製造方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788209A (fr) 1971-09-01 1973-02-28 Pfizer Derives tetrazoyliques des prostaglandines naturelles
NL7401493A (pl) 1973-02-08 1974-08-12
US4705806A (en) * 1978-02-13 1987-11-10 Morton Jr Douglas R Prostacyclin analogs
US4565827A (en) * 1980-10-27 1986-01-21 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. 7-Substituted PGI2 -derivatives and pharmaceutical compositions containing them
AU617121B2 (en) * 1987-07-17 1991-11-21 Nutrasweet Company, The Substituted guanidines containing a tetrazolyl moiety and their use as high potency sweetening agents
AU3578489A (en) * 1988-07-12 1990-02-05 Nutrasweet Company, The High potency sweetening agents
US4881288A (en) * 1988-07-13 1989-11-21 Tennant Trend Inc. Center feed dispenser for cleaning solution
JP2500371B2 (ja) 1993-11-08 1996-05-29 工業技術院長 半導体薄膜の成長方法
JP3769738B2 (ja) * 1994-04-11 2006-04-26 旭硝子株式会社 ジフルオロプロスタサイクリン類
JPH08217772A (ja) 1995-02-13 1996-08-27 Asahi Glass Co Ltd ジフルオロ置換ビニルエーテル類の製造方法
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
JP3598611B2 (ja) 1995-10-17 2004-12-08 旭硝子株式会社 ジフルオロ化合物の製造方法
ES2171742T3 (es) 1995-11-14 2002-09-16 Toray Industries Agente reductor de la presion ocular.
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
AUPO440696A0 (en) 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
EP0947195A4 (en) 1997-03-14 1999-12-01 Toray Industries NERVOUS CELL PROTECTIVE AGENTS
IT1299191B1 (it) 1998-06-23 2000-02-29 Sigma Tau Healthscience Spa Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
EP1044972A4 (en) 1998-10-23 2003-03-12 Toray Industries 5,7,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND MEDICAMENTS CONTAINING SAID DERIVATIVE
KR20040015364A (ko) * 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
JP2005534653A (ja) 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
JP5007169B2 (ja) 2007-02-20 2012-08-22 カルソニックカンセイ株式会社 電動コンプレッサ
EP1988087A1 (en) 2007-03-28 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of autoimmune diseases
JP2009168193A (ja) 2008-01-18 2009-07-30 Nachi Fujikoshi Corp 遊星歯車減速機
BRPI0918134B1 (pt) 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747531A (en) 1994-02-17 1998-05-05 Asahi Glass Company Ltd. Difluoroprostacyclins
JP2004256547A (ja) 1994-03-17 2004-09-16 Asahi Glass Co Ltd ジハロゲン化プロスタサイクリン類の製造方法

Also Published As

Publication number Publication date
US8877787B2 (en) 2014-11-04
JP5468007B2 (ja) 2014-04-09
EP2343292B1 (en) 2014-08-06
RU2509768C2 (ru) 2014-03-20
MX2011002573A (es) 2011-07-28
CA2736039A1 (en) 2010-03-18
AU2009292555A1 (en) 2010-03-18
AU2009292555B2 (en) 2014-05-29
US8691857B2 (en) 2014-04-08
US9034906B2 (en) 2015-05-19
US8394844B2 (en) 2013-03-12
BRPI0918134A2 (pt) 2016-03-01
US20150018401A1 (en) 2015-01-15
EP2343292A1 (en) 2011-07-13
BRPI0918134B1 (pt) 2019-02-12
CN102209719B (zh) 2014-05-14
KR20110051286A (ko) 2011-05-17
US20130072530A1 (en) 2013-03-21
US20140128441A1 (en) 2014-05-08
WO2010029925A1 (ja) 2010-03-18
CN102209719A (zh) 2011-10-05
ES2522971T3 (es) 2014-11-19
DK2343292T3 (da) 2014-11-03
PL2343292T3 (pl) 2015-01-30
EP2343292A4 (en) 2012-03-21
CA2736039C (en) 2016-06-07
JPWO2010029925A1 (ja) 2012-02-02
US20110098481A1 (en) 2011-04-28
PT2343292E (pt) 2014-11-04
RU2011113967A (ru) 2012-10-27

Similar Documents

Publication Publication Date Title
KR101645752B1 (ko) 신규의 프로스타글란딘 ｉ2 유도체
JP6859323B2 (ja) カルボキシ置換（ヘテロ）芳香環誘導体並びにその調製方法及び使用
KR101760970B1 (ko) 신규의 ep4 아고니스트
WO2015154716A1 (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
KR20020033785A (ko) 프로스타글란딘 ｅ 유사체
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
US20030220385A1 (en) Treatment of disorder related to low cyclic GMP levels

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
FPAY Annual fee payment

Payment date: 20190725

Year of fee payment: 4